Long noncoding RNA expression in acute lymphoblastic leukemia: A systematic review

• Published in: Critical reviews in oncology/hematology 2024-04, Vol.196, p.104290-104290, Article 104290
• Main Authors: Lobo-Alves, Sara Cristina, Oliveira, Liana Alves de, Kretzschmar, Gabriela Canalli, Valengo, Andressa Eloisa, Rosati, Roberto
• Format: Article
• Language: English
• Subjects: Acute lymphoblastic leukemia; CRNDE; Differential gene expression; Leukemia; LINC01013; Long noncoding RNA; Noncoding RNA; Transcriptome
• ISSN: 1040-8428; 1879-0461
• DOI: 10.1016/j.critrevonc.2024.104290

Long noncoding RNAs (lncRNAs), as gene expression modulators, are potential players in Acute Lymphoblastic Leukemia (ALL) pathogenesis. We systematically explored current literature on lncRNA expression in ALL to identify lncRNAs consistently reported as differentially expressed (DE) either in ALL versus controls or between ALL subtypes. By comparing articles that provided global expression data for DE lncRNAs in the ETV6::RUNX1-positive ALL subtype, we identified four DE lncRNAs in three independent studies (two versus other subtypes and one versus controls), showing concordant expression of LINC01013, CRNDE and lnc-KLF7–1. Additionally, LINC01503 was consistently downregulated on ALL versus controls. Within RT-qPCR studies, twelve lncRNA were DE in more than one source. Thus, several lncRNAs were supported as DE in ALL by multiple sources, highlighting their potential role as candidate biomarkers or therapeutic targets. Finally, as lncRNA annotation is rapidly expanding, standardization of reporting and nomenclature is urgently needed to improve data verifiability and compilation. [Display omitted] •LncRNAs are promising biomarkers in Acute Lymphoblastic Leukemia (ALL).•CRNDE was consistently upregulated in ALL patients.•LINC1503 was detected downregulated in ALL patients.•Efforts are needed to improve consistency and allow systematization of lncRNA data.